Euglycemic diabetic ketoacidosis: The paradox of delayed correction of acidosis

被引:1
作者
Albert, Stewart G. [1 ,2 ]
Shrestha, Ekta [1 ]
Wood, Emily M. [1 ]
机构
[1] St Louis Univ, Sch Med, Div Endocrinol, Dept Internal Med, St Louis, MO USA
[2] St Louis Univ, Dept Internal Med, Div Endocrinol, Sch Med, SLUCare Acad Pavil, 1008 South Spring St, St Louis, MO 63110 USA
关键词
Diabetic ketoacidosis; Euglycemic diabetic ketoacidosis; Delta-delta anion gap acidosis; INSULIN INFUSION PROTOCOL; HYPERGLYCEMIA; SYSTEM; SAFE;
D O I
10.1016/j.dsx.2023.102848
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The effectiveness of standard treatment for diabetic ketoacidosis (DKA) in "euglycemic DKA" (EuDKA, blood glucose (BG) <= 250 mg/dL) was evaluated with respect to the time to correction of BG <= 200 mg/dL, anion gap (AG)<= 12 mmol/L, and serum bicarbonate [HCO3] >= 18 mmol/L. Methods: Data were retrieved from an electronic health record (EPIC) for "diabetic ketoacidosis." Patients were categorized by initial BG as EuDKA, middle range DKA (MrDKA, >250 < 600 mg/dL) and hyperosmolar DKA (HyperDKA >= 600 mg/dL). Results: There were 56 patients (27men, 29women; age 45.8 +/- 15.6 (SD) years. The initial 8-h insulin infusion rate (0.05 +/- 0.02, 0.09 +/- 0.03, 0.14 +/- 0.05units/kg/h, p < 0.001) and the time to correction of BG (3.4 +/- 1.9, 6.1 +/- 2.9 and 9.6 +/- 3.9 h, p < 0.001), differed for EuDKA, MrDKA and HyperDKA. There were no differences in the time to correction of AG or [HCO3]. The earlier time to correction of BG in EuDKA resulted in paradoxical longer lag times for correction of [HCO3] (p = 0.003) and AG (p = 0.048). Changes in BG, AG and [HCO3] correlated with insulin infusion rates of 0.08-0.1units/kg/h whereas in EuDKA the insulin infusion rate was 0.05 +/- 0.02 units/kg/h. Conclusion: In EuDKA, correlation analyses suggest that higher glucose and insulin infusion rates than what would be projected for the level of blood glucose are required to reverse ketoacidosis. Prospective trials are required to optimize the levels of glucose and insulin infusions in EuDKA.
引用
收藏
页数:4
相关论文
共 24 条
  • [11] The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Holt, Richard I. G.
    DeVries, J. Hans
    Hess-Fischl, Amy
    Hirsch, Irl B.
    Kirkman, M. Sue
    Klupa, Tomasz
    Ludwig, Barbara
    Norgaard, Kirsten
    Pettus, Jeremy
    Renard, Eric
    Skyler, Jay S.
    Snoek, Frank J.
    Weinstock, Ruth S.
    Peters, Anne L.
    [J]. DIABETES CARE, 2021, 44 (11) : 2589 - 2625
  • [12] John Samuel M, 2018, Diabetes Spectr, V31, P26, DOI 10.2337/ds16-0061
  • [13] Hyperglycemic Crises in Adult Patients with Diabetes
    Kitabchi, Abbas E.
    Umpierrez, Guillermo E.
    Miles, John M.
    Fisher, Joseph N.
    [J]. DIABETES CARE, 2009, 32 (07) : 1335 - 1343
  • [14] Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
    Liu, Jiali
    Li, Ling
    Li, Sheyu
    Wang, Yuning
    Qin, Xuan
    Deng, Ke
    Liu, Yanmei
    Zou, Kang
    Sun, Xin
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (09) : 1619 - 1627
  • [15] Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management
    Long, Brit
    Lentz, Skyler
    Koyfman, Alex
    Gottlieb, Michael
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2021, 44 : 157 - 160
  • [16] METABOLIC EFFECTS OF LOW-DOSE INSULIN THERAPY ON GLUCOSE-METABOLISM IN DIABETIC-KETOACIDOSIS
    LUZI, L
    BARRETT, EJ
    GROOP, LC
    FERRANNINI, E
    DEFRONZO, RA
    [J]. DIABETES, 1988, 37 (11) : 1470 - 1477
  • [17] Modi A, 2017, CURR DIABETES REV, V13, P315, DOI 10.2174/1573399812666160421121307
  • [18] EUGLYCEMIC DIABETIC KETOACIDOSIS
    MUNRO, JF
    CAMPBELL, IW
    MCCUISH, AC
    DUNCAN, LJP
    [J]. BRITISH MEDICAL JOURNAL, 1973, 2 (5866) : 578 - 580
  • [19] Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition
    Peters, Anne L.
    Buschur, Elizabeth O.
    Buse, John B.
    Cohan, Pejman
    Diner, Jamie C.
    Hirsch, Irl B.
    [J]. DIABETES CARE, 2015, 38 (09) : 1687 - 1693
  • [20] Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
    Rosenstock, Julio
    Ferrannini, Ele
    [J]. DIABETES CARE, 2015, 38 (09) : 1638 - 1642